About Us LifeGen Technologies is discovering the genes associated with aging by using gene chips to compare the activity of thousands of genes in young and aged animals and humans. The same approach is being used to study how the aging process is retarded by caloric restriction (CR), which is the only intervention proven to retard aging in warm blooded animals. LifeGen has a patent application pending for the use of such "gene expression profiling" as a method to measure the progression of the aging process at the molecular level in individual organs.  This approach should facilitate the identification of targets for new drugs and the evaluation of the ability of existing pharmaceutical or nutraceutical compounds to retard aging in individual organs. To aid these latter studies, LifeGen has built a large bank of tissues from mice treated with specific nutrients from middle age to old age. LifeGen is developing a proprietary database on the genetics of aging and on the effects of drugs and nutraceuticals on aging and related diseases in animals. The database includes gene expression profiles of normal aging in experimental animals, age-related diseases in special animal models, and retarded aging in animals on CR.  LifeGen has already used its database to identify genes which may underlie the aging process in multiple tissues as well as other genes which may underlie the actions of CR. LifeGen has four divisions: Animal Health, Human Nutraceuticals, Diagnostics, and Drug Target Discovery. The company is establishing strategic partnerships with established companies in these areas which will provide both short- and long-term revenues. Profile | Board of Directors | News